Citations (21)
Keep up to date with the latest research on this topic with citation updates for this article.
Read on this site (6)
Madeline Merkel, David Danese, Chongshu Chen, Jessie Wang, Aozhou Wu, Hongbo Yang & Hollis Lin. (2023) Indirect treatment comparison (ITC) of the efficacy of vutrisiran and tafamidis for hereditary transthyretin-mediated amyloidosis with polyneuropathy. Expert Opinion on Pharmacotherapy 24:10, pages 1205-1214.
Read now
Read now
Ana Peláez Bejarano, Maria de las Aguas Robustillo Cortés & Maria Isabel Guzman Ramos. (2021) Patient experience in a rare disease: application of the IEXPAC questionnaire in hereditary transthyretin-mediated amyloidosis. Expert Opinion on Orphan Drugs 9:6, pages 175-180.
Read now
Read now
Peter Gorevic, Jaclyn Franklin, Jihong Chen, Gautam Sajeev, Jessie C. H. Wang & Hollis Lin. (2021) Indirect treatment comparison of the efficacy of patisiran and inotersen for hereditary transthyretin-mediated amyloidosis with polyneuropathy. Expert Opinion on Pharmacotherapy 22:1, pages 121-129.
Read now
Read now
Imtiaz A. Samjoo, Elizabeth M. Salvo, Diana Tran, Leslie Amass, Michelle Stewart & Chris Cameron. (2020) The impact of clinical heterogeneity on conducting network meta-analyses in transthyretin amyloidosis with polyneuropathy. Current Medical Research and Opinion 36:5, pages 799-808.
Read now
Read now
Hollis Lin, Sonalee Agarwal, Marissa Betts, Kyle Fahrbach, Madhura Chitnis & Michael Polydefkis. (2019) Response to the letter to the editor on “an indirect treatment comparison of the efficacy of patisiran and tafamidis for the treatment of hereditary transthyretin-mediated amyloidosis with polyneuropathy”. Expert Opinion on Pharmacotherapy 20:12, pages 1529-1530.
Read now
Read now
E. M. Salvo, I. A. Samjoo, D. Tran & C. Cameron. (2019) Letter to the editor concerning the article: “An indirect treatment comparison of the efficacy of patisiran and tafamidis for the treatment of hereditary transthyretin-mediated amyloidosis with polyneuropathy”. Expert Opinion on Pharmacotherapy 20:12, pages 1527-1528.
Read now
Read now
Articles from other publishers (15)
Osnat Itzhaki Ben Zadok & Rodney H. Falk. (2023) Variant and wild type transthyretin amyloidosis: two sides of the same coin or different currencies in different pockets?. European Journal of Heart Failure 25:4, pages 525-527.
Crossref
Crossref
Efthimios Dardiotis & Theodoros Kyriakides. (2023) Drug and Gene Therapy for Treating Variant Transthyretin Amyloidosis
(ATTRv) Neuropathy. Current Neuropharmacology 21:3, pages 471-481.
Crossref
Crossref
Intissar Anan, Ole B. Suhr, Katarzyna Liszewska, Jorge Mejia Baranda, Björn Pilebro, Jonas Wixner & Elisabet Ihse. (2022) Amyloid fibril composition type is consistent over time in patients with Val30Met (p.Val50Met) transthyretin amyloidosis. PLOS ONE 17:3, pages e0266092.
Crossref
Crossref
Can Ebru Bekircan-Kurt, Ezgi Yilmaz, Doruk Arslan, Fatma Gokcem Yildiz, Özlem Dikmetas, Zeynep Ergul-Ulger, Sibel Kocabeyoglu, Murat Irkec, Vedat Hekimsoy, Lale Tokgozoglu, Ersin Tan & Sevim Erdem-Ozdamar. (2022) The functional and structural evaluation of small fibers in asymptomatic carriers of TTR p.Val50Met (Val30Met) mutation. Neuromuscular Disorders 32:1, pages 50-56.
Crossref
Crossref
Bin Zhong, Xianhua Huang, Yizhou Zheng, Xiaohua Guo & Longhuo Wu. (2021) The discovery and development of transthyretin amyloidogenesis inhibitors: what are the lessons?. Future Medicinal Chemistry 13:23, pages 2083-2105.
Crossref
Crossref
Massimo Russo, Luca Gentile, Vincenzo Di Stefano, Gianluca Di Bella, Fabio Minutoli, Antonio Toscano, Filippo Brighina, Giuseppe Vita & Anna Mazzeo. (2021) Use of Drugs for ATTRv Amyloidosis in the Real World: How Therapy Is Changing Survival in a Non-Endemic Area. Brain Sciences 11:5, pages 545.
Crossref
Crossref
Luca Gentile, Massimo Russo, Marco Luigetti, Giulia Bisogni, Andrea Di Paolantonio, Angela Romano, Valeria Guglielmino, Ilenia Arimatea, Mario Sabatelli, Antonio Toscano, Giuseppe Vita & Anna Mazzeo. (2021) Patisiran in hATTR Amyloidosis: Six-Month Latency Period before Efficacy. Brain Sciences 11:4, pages 515.
Crossref
Crossref
Meissane Benbrahim, Kelsey Norman, Vaishali Sanchorawala, Omar K Siddiqi & David Hughes. (2021) A review of novel agents and clinical considerations in patients with ATTR cardiac amyloidosis. Journal of Cardiovascular Pharmacology Publish Ahead of Print.
Crossref
Crossref
Ivan Urits, Daniel Swanson, Michael C. Swett, Anjana Patel, Kevin Berardino, Ariunzaya Amgalan, Amnon A. Berger, Hisham Kassem, Alan D. Kaye & Omar Viswanath. (2020) A Review of Patisiran (ONPATTRO®) for the Treatment of Polyneuropathy in People with Hereditary Transthyretin Amyloidosis. Neurology and Therapy 9:2, pages 301-315.
Crossref
Crossref
Hollis Lin, Madeline Merkel, Cecilia Hale & Jing L Marantz. (2020) Experience of patisiran with transthyretin stabilizers in patients with hereditary transthyretin-mediated amyloidosis. Neurodegenerative Disease Management 10:5, pages 289-300.
Crossref
Crossref
Simoneide S. Titze-de-Almeida, Pedro Renato de Paula Brandão, Ingrid Faber & Ricardo Titze-de-Almeida. (2019) Leading RNA Interference Therapeutics Part 1: Silencing Hereditary Transthyretin Amyloidosis, with a Focus on Patisiran. Molecular Diagnosis & Therapy 24:1, pages 49-59.
Crossref
Crossref
Saša A Živković. (2020) Neuropathy Associated with Hereditary Transthyretin Amyloidosis—Diagnosis and Management. US Neurology 16:2, pages 103.
Crossref
Crossref
Yuhua Weng, Haihua Xiao, Jinchao Zhang, Xing-Jie Liang & Yuanyu Huang. (2019) RNAi therapeutic and its innovative biotechnological evolution. Biotechnology Advances 37:5, pages 801-825.
Crossref
Crossref
Yvette N. Lamb & Emma D. Deeks. (2019) Tafamidis: A Review in Transthyretin Amyloidosis with Polyneuropathy. Drugs 79:8, pages 863-874.
Crossref
Crossref
Giuseppe Vita, Gian Luca Vita, Claudia Stancanelli, Luca Gentile, Massimo Russo & Anna Mazzeo. (2019) Genetic neuromuscular disorders: living the era of a therapeutic revolution. Part 1: peripheral neuropathies. Neurological Sciences 40:4, pages 661-669.
Crossref
Crossref